Filing Flows › Editas Medicine (EDIT) › Q4 2025
Editas Medicine (EDIT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 9, 2026
Editas Medicine (EDIT) reported revenue of $24.7M for the fourth quarter 2025 (Q4 2025), -19% from a year earlier and +228% from the quarter before. Operating margin was -31.3%, net loss $5.6M (22.7% of revenue).
Editas Medicine, Q4 2025: revenue $24.7M (-19% year over year), operating margin -31.3%, net loss $5.6M, operating cash flow −$36.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.7M | +228% | -19% |
| Operating profit | −$7.8M | — | — |
| Net earnings | −$5.6M | — | — |
| Operating cash flow | −$36.4M | — | — |
What changed
Revenue was $24.7M in Q4 2025, down 19% year over year and up 228% from the previous quarter.
Operating costs exceeded revenue by $7.8M, an operating margin of -31.3%. Total costs fell 58% while revenue fell 19%. The quarter ended with a net loss of $5.6M, narrower than the previous quarter's $25.1M loss. Non-operating items added $2.1M, -38% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$36.4M. Non-cash charges added back $805K of depreciation and $2.1M of share-based compensation. Working capital and other items used $33.7M. Capital expenditures of $60K exceeded it, leaving free cash flow of −$36.4M.
Questions
What was Editas Medicine's revenue in the fourth quarter 2025?
Editas Medicine (EDIT) reported revenue of $24.7M for the fourth quarter 2025 (Q4 2025), -19% from a year earlier and +228% from the quarter before.
Was Editas Medicine profitable in the fourth quarter 2025?
Operating loss was $7.8M (-31.3% of revenue) and net loss $5.6M.
Source: Editas Medicine 10-K on SEC EDGAR.